Agency
Beth Israel Deaconess Hospital Plymouth, INC.
Beth Israel Deaconess Hospital Plymouth, INC. was paid $11.55M by Medicaid between Jan 2018 and Nov 2024, across 123 billing codes. Its largest line is T2046, Hospice long term care, room and board only; per diem — 88% of everything it billed.
33Billing provider infoBETH ISRAEL DEACONESS HOSPITAL PLYMOUTH, INC.
PLYMOUTH, MA 02360
PLYMOUTH, MA 02360
33aNPI1164535084assigned 08/16/2006
33bProvider typeCommunity Based Hospice Care Agency
28Total paid$11.55M
24GClaims77,743
24DCodes billed123
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Community Based Hospice Care Agency providers in Massachusetts
Rank by total paid#19 of 71
Median peer was paid$4.97M
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,300 | $1.76M | |
| 2019 | 7,050 | $1.21M | |
| 2020 | 8,873 | $1.10M | |
| 2021 | 20,419 | $1.91M | |
| 2022 | 21,926 | $2.51M | |
| 2023 | 3,798 | $1.87M | |
| 2024incomplete | 3,377 | $1.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T2046 | Hospice long term care, room and board only; per diem | 88% | 2,341 | 2,121 | $10.12M |
| G0378 | Hospital observation service, per hour | 1.6% | 567 | 239 | $184K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.4% | 751 | 722 | $161K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.4% | 678 | 650 | $157K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 849 | 295 | $94K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,152 | 1,091 | $89K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 189 | 186 | $72K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 245 | 207 | $49K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | <1% | 303 | 253 | $46K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 623 | 222 | $45K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 330 | 330 | $38K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 245 | 184 | $35K |
111 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 53 | $31K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,151 | $28K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 209 | $25K |
| 80053 | Comprehensive metabolic panel | <1% | 1,975 | $24K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 106 | $20K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 125 | $18K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 303 | $16K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 257 | $16K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 330 | $16K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 461 | $15K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 461 | $14K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,863 | $13K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 71 | $13K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 68 | $11K |
| 76642 | <1% | 83 | $11K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 417 | $11K |
| 97161 | <1% | 87 | $10K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 317 | $9K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 48 | $8K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 58 | $8K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 302 | $7K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 213 | $7K |
| 87481 | <1% | 180 | $6K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 180 | $6K |
| 80050 | General health panel | <1% | 324 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 477 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 321 | $5K |
| G0299 | Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes | <1% | 11,537 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 180 | $5K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 72 | $5K |
| 85027 | <1% | 728 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 165 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 525 | $4K |
| 84484 | <1% | 276 | $4K | |
| 82607 | <1% | 275 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 202 | $4K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 42 | $3K |
| 83735 | <1% | 502 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 13 | $3K |
| 80061 | Lipid panel | <1% | 883 | $3K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 145 | $3K |
| 82728 | <1% | 232 | $3K | |
| 86803 | <1% | 211 | $3K | |
| 84439 | <1% | 300 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 272 | $2K |
| 84703 | <1% | 306 | $2K | |
| 86780 | <1% | 168 | $2K | |
| 83690 | <1% | 285 | $2K | |
| 87081 | <1% | 309 | $2K | |
| 84466 | <1% | 141 | $2K | |
| 85610 | <1% | 396 | $1K | |
| 83540 | <1% | 210 | $1K | |
| 86618 | <1% | 77 | $1K | |
| 86850 | <1% | 149 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 48 | $1K |
| 84702 | <1% | 78 | $1K | |
| 81001 | <1% | 344 | $981.58 | |
| 87070 | <1% | 124 | $950.88 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 334 | $879.96 |
| 73610 | <1% | 27 | $857.40 | |
| G0155 | Services of clinical social worker in home health or hospice settings, each 15 minutes | <1% | 2,299 | $852.47 |
| 87186 | <1% | 97 | $815.38 | |
| 82570 | <1% | 152 | $750.06 | |
| 84153 | <1% | 40 | $671.20 | |
| 87340 | <1% | 69 | $649.98 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 371 | $644.14 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 177 | $630.64 |
| 73630 | <1% | 26 | $586.91 | |
| 86900 | <1% | 149 | $572.04 | |
| 82948 | <1% | 76 | $506.04 | |
| 87430 | <1% | 44 | $484.38 | |
| 86140 | <1% | 99 | $482.50 | |
| 82248 | <1% | 548 | $481.75 | |
| 80076 | <1% | 114 | $457.13 | |
| 86901 | <1% | 149 | $455.04 | |
| 85652 | <1% | 156 | $414.94 | |
| 81003 | <1% | 186 | $404.05 | |
| 71045 | Radiologic examination, chest; single view | <1% | 127 | $390.41 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 338 | $390.19 |
| 82043 | <1% | 71 | $386.58 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 234 | $349.80 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 210 | $318.94 |
| 85730 | <1% | 51 | $291.48 | |
| 83516 | <1% | 25 | $284.04 | |
| 82172 | <1% | 13 | $202.54 | |
| 84100 | <1% | 338 | $201.67 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 144 | $176.08 |
| 83695 | <1% | 13 | $153.53 | |
| 83525 | <1% | 14 | $146.02 | |
| 87807 | <1% | 16 | $142.22 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 276 | $138.57 |
| 85379 | <1% | 12 | $106.12 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 74 | $85.00 |
| 81025 | <1% | 13 | $82.68 | |
| 85018 | <1% | 24 | $61.78 | |
| 82565 | <1% | 19 | $51.20 | |
| J2704 | Injection, propofol, 10 mg | <1% | 525 | $43.89 |
| 85007 | <1% | 13 | $40.69 | |
| 84460 | <1% | 33 | $38.80 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 314 | $13.47 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 58 | $5.67 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 170 | $4.51 |
| Q5004 | Hospice care provided in skilled nursing facility (snf) | 0% | 14,586 | $0.00 |
| G0156 | Services of home health/hospice aide in home health or hospice settings, each 15 minutes | 0% | 10,495 | $0.00 |
| G0300 | Direct skilled nursing services of a licensed practical nurse (lpn) in the home health or hospice setting, each 15 minutes | 0% | 949 | $0.00 |
| Q5001 | Hospice or home health care provided in patient's home/residence | 0% | 5,069 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 410 | $0.00 |
| 76830 | Ultrasound, transvaginal | 0% | 12 | $0.00 |
| 80143 | 0% | 23 | $0.00 | |
| 81513 | 0% | 25 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRADZEVICH, JASON (V.P. OF FINANCE AND CFO)
| Provider | Location | Paid |
|---|---|---|
| Beth Israel Deaconess Hospital Plymouth, INC. | Plymouth, MA | $35.03M |
| Beth Israel Deaconess Hospital Plymouth, INC. | Plymouth, MA | $875K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.